Citations

Mayo Clinic

Showing 10 of 108551 citations.

Motion – The Available Treatments for Hepatitis C Are Cost Effective: Arguments against the Motion
Kim, W. Ray

Canadian Journal of Gastroenterology | March 20, 2016 | Volume: 16 | Issue: 10 | Pages: 710-715

10.1155/2002/398016 | PMID 12420033 Get It

Hepatitis C is a prevalent infection in North America. However, the natural history of hepatitis C virus (HCV) infection in the general population is not fully understood. Available cohortbased studies suggest that only a relative minority of patients develop significant liver disease, such as cirrhosis and/or hepatocellular carcinoma. Other studies, mostly conducted based on referral patients with established disease, portray much more serious consequences of HCV infection. Although a substantial improvement has been made in the treatment for HCV, the overall impact of antiviral therapy in altering the natural course of HCV infection remains uncertain. Therapeutic trials involve narrow selection criteria that would exclude the majority of hepatitis C patients in the community, and are conducted in ideal settings that may not be generalizable to the average practice setting. Demographic groups that are at high risk of developing severe liver disease include older male patients who consume alcohol. In contrast, antiviral therapy is more effective in young and female patients and those who do not drink alcohol. Thus, patients who appear to be successfully treated may not be those for whom clearance of the virus would be beneficial. Cost-effectiveness studies published to date have not been able to fully address the complex and heterogeneous matrix of the factors that influence the natural history of HCV infection and treatment response.In summary, there is a significant degree of uncertainty about many assumptions that are necessary in creating computer models to estimate the cost-effectiveness of HCV therapy. When interpreting the results of cost effectiveness analyses regarding the treatment of HCV infection, it is important to be aware of the underlying assumptions that are incorporated in the model and the data on which they are based. Given these limitations, vis-à-vis the expense, toxicity and yet limited effectiveness of the currently available antiviral agents, one should not blindly accept a conclusion that treatment for hepatitis C is cost effective.
Identifying Contraindication to Resection in Patients with Pancreatic Carcinoma: The Role of Endoscopic Ultrasound
Wiersema, Maurits J.

Canadian Journal of Gastroenterology | March 20, 2016 | Volume: 16 | Issue: 2 | Pages: 109-114

10.1155/2002/324594 | PMID 11875595 Get It

OBJECTIVE: To present recently published material comparing the performance of endosonography relative to other imaging modalities when evaluating the patient with a suspected or known pancreas carcinoma.METHODS: Medline was searched using the terms ‘endosonography’ and ‘pancreas neoplasms’. References from retrieved papers were reviewed to identify other reports. Emphasis was placed on peer-reviewed material published within the past three years that included comparison with other imaging modalities.RESULTS: Despite advances in cross-sectional imaging modalities, endosonography remains the most sensitive and specific method for identifying pancreatic mass lesions. The resectability of pancreatic carcinoma is best determined with dual-phase helical computed tomography, although endosonography may be slightly more accurate for lymph node assessment. Endoscopic ultrasound-guided fine needle aspiration biopsy has a high sensitivity (93%) and specificity (100%) when used in patients with masses in whom pancreatic cancer is suspected but prior biopsies have been negative.CONCLUSIONS: Endosonography helps in the diagnosis of pancreatic neoplasms through definitive inclusion or exclusion of a mass lesion as well as biopsy confirmation of malignancy. The role of endosonography in the determination of resectability has been eclipsed by dual-phase helical computed tomography. However, endoscopic ultrasound with fine needle aspiration of nonperitumoral lymph nodes may identify advanced disease with sufficient frequency to justify its routine use in patients with lesions that are thought to be resectable based on helical computed tomography.
Severe Allergic Contact Dermatitis to Dermabond Prineo, a Topical Skin Adhesive of 2-Octyl Cyanoacrylate Increasingly Used in Surgeries to Close Wounds
Davis, Mark D. P. , Davis, Mark D.P. , Stuart, Michael J.

Dermatitis® | March 19, 2016 | Volume: 27 | Issue: 2 | Pages: 75-76

10.1097/der.0000000000000163 | PMID 26983096 Get It

Blood lipids and prostate cancer: a Mendelian randomization analysis
Bonilla, Carolina , Holly, Jeff M.P. , Perks, Claire M. , Davies, Neil M , Haycock, Philip , Richards, J. Brent , Eeles, Rosalind A. , Easton, Doug , Olama, Ali Amin Al , Benlloch, Sara, MacInnis, Robert J. , Grönberg, Henrik , Haiman, Christopher A. , Schleutker, Johanna , Nordestgaard, Børge G. , Travis, Ruth C. , Neal, David E. , Pashayan, Nora , Stanford, Janet L. , Blot, William J. , Thibodeau, Stephen N. , Maier, Christiane, Kibel, Adam S. , Brenner, Hermann , Park, Jong, Kaneva, Radka , Batra, Jyotsna , Teixeira, Manuel R. , Micheal, Agnieszka, Pandha, Hardev , Smith, George Davey , Lewis, Sarah J. , Martin, Richard M. , Thibodeau, Stephen, Bull, Caroline J. , Yu, Oriana Hoi Yun , Kote‐Jarai, Zsofia , Muir, Kenneth , Giles, Graham G. , Wiklund, Fredrik E. , Khaw, Kay‐Tee , Cybulski, Cezary , Cannon‐Albright, Lisa , Teixeira, Manuel R , Eeles, Rosalind A , Schleutker, Johanna , Travis, Ruth C , Pashayan, Nora , Maclnnis, Robert , Haycock, Philip , Brenner, Hermann , Martin, Richard M , Batra, Jyotsna , Davey Smith, George

Cancer Medicine | March 19, 2016 | Volume: 5 | Issue: 6 | Pages: 1125-1136

10.1002/cam4.695 | PMID 26992435 Get It

AbstractGenetic risk scores were used as unconfounded instruments for specific lipid traits (Mendelian randomization) to assess whether circulating lipids causally influence prostate cancer risk. Data from 22,249 prostate cancer cases and 22,133 controls from 22 studies within the international PRACTICAL consortium were analyzed. Allele scores based on single nucleotide polymorphisms (SNPs) previously reported to be uniquely associated with each of low‐density lipoprotein (LDL), high‐density lipoprotein (HDL), and triglyceride (TG) levels, were first validated in an independent dataset, and then entered into logistic regression models to estimate the presence (and direction) of any causal effect of each lipid trait on prostate cancer risk. There was weak evidence for an association between the LDL genetic score and cancer grade: the odds ratio (OR) per genetically instrumented standard deviation (SD) in LDL, comparing high‐ (≥7 Gleason score) versus low‐grade (<7 Gleason score) cancers was 1.50 (95% CI: 0.92, 2.46; P = 0.11). A genetically instrumented SD increase in TGs was weakly associated with stage: the OR for advanced versus localized cancer per unit increase in genetic risk score was 1.68 (95% CI: 0.95, 3.00; P = 0.08). The rs12916‐T variant in 3‐hydroxy‐3‐methylglutaryl‐CoA reductase (HMGCR) was inversely associated with prostate cancer (OR: 0.97; 95% CI: 0.94, 1.00; P = 0.03). In conclusion, circulating lipids, instrumented by our genetic risk scores, did not appear to alter prostate cancer risk. We found weak evidence that higher LDL and TG levels increase aggressive prostate cancer risk, and that a variant in HMGCR (that mimics the LDL lowering effect of statin drugs) reduces risk. However, inferences are limited by sample size and evidence of pleiotropy.
Aspirin dosage for the prevention of graft occlusion in people undergoing coronary surgery
Alahdab, Fares , Jazayerli, Mhd Luay, Alhalabi, Omar , Mallak, Mahmoud, Haydour, Qusay, Murad, M. Hassan , Alhalabi, Omar , Hasan, Somar M. , Alkhouli, Mohamad , Murad, M Hassan , Alahdab, Fares

Cochrane Database of Systematic Reviews | March 19, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/14651858.cd012113 Get It

Hepatitis C Treatment in 2016: Reasons to Be an OPTIMIST
Vargas, Hugo E. , Vargas, Hugo E

Hepatology | March 19, 2016 | Volume: 64 | Issue: 2 | Pages: 330-332

10.1002/hep.28559 | PMID 26992027 Get It

REG3β Plays a Key Role in IL17RA Protumoral Effect—Response
Loncle, Céline, Bonjoch, Laia , Folch‐Puy, Emma , López‐Millán, Belén , Lac, Sophie, Molejon, María Inés , Chuluyán, Eduardo , Cordelier, Pierre , Dubus, Pierre , Lomberk, Gwen , Closa, Daniel , Urrutia, Raúl , Iovanna, Juan , Lomberk, Gwen L

Cancer Research | March 19, 2016 | Volume: 76 | Issue: 7 | Pages: 2051-2051

10.1158/0008-5472.can-15-3355 | PMID 26992425 Get It

Hypothermia/rewarming disrupts excitation-contraction coupling in cardiomyocytes
Schaible, Niccole , Han, Young Soo, Hoàng, Thủy , Arteaga, Grace M. , Tveita, Torkjel , Sieck, Gary C. , Arteaga, Grace, Sieck, Gary

American Journal of Physiology-Heart and Circulatory Physiology | March 19, 2016 | Volume: 310 | Issue: 11 | Pages: H1533-H1540

10.1152/ajpheart.00840.2015 | PMID 26993227 Get It

Hypothermia/rewarming (H/R) is poorly tolerated by the myocardium; however, the underlying intracellular basis of H/R-induced cardiac dysfunction remains elusive. We hypothesized that in cardiomyocytes, H/R disrupts excitation-contraction coupling by reducing myofilament Ca2+sensitivity due to an increase in cardiac troponin I (cTnI) phosphorylation. To test this hypothesis, isolated rat cardiomyocytes (13–15 cells from 6 rats per group) were electrically stimulated to evoke both cytosolic Ca2+([Ca2+]cyto) and contractile (sarcomere shortening) responses that were simultaneously measured using an IonOptix system. Cardiomyocytes were divided into two groups: 1) those exposed to hypothermia (15°C for 2 h) followed by rewarming (35°C; H/R); or 2) time-matched normothermic (35°C) controls (CTL). Contractile dysfunction after H/R was indicated by reduced velocity and extent of sarcomere length (SL) shortening compared with time-matched controls. Throughout hypothermia, basal [Ca2+]cytoincreased and the duration of evoked [Ca2+]cytotransients was prolonged. Phase-loop plots of [Ca2+]cytovs. contraction were shifted rightward in cardiomyocytes during hypothermia compared with CTL, indicating a decrease in Ca2+sensitivity. Using Western blot, we found that H/R increases cTnI phosphorylation. These results support our overall hypothesis and suggest that H/R disrupts excitation-contraction coupling of cardiomyocytes due to increased cTnI phosphorylation and reduced Ca2+sensitivity.Listen to this article's corresponding podcast at http://ajpheart.podbean.com/e/hypothermiarewarming-disrupts-e-c-coupling/ .
FOXA1 defines cancer cell specificity
Zhang, Gaihua , Zhao, Yongbing , Kao, Li-Pin, Skerry, Benjamin, Li, Zhaoyu , Li, Zhaoyu , Liu, Yi Sha , Wang, Xiao

Science Advances | March 19, 2016 | Volume: 2 | Issue: 3 | Pages: No page available

10.1126/sciadv.1501473 | PMID 27034986 Get It

Functional FOXA1 targeting is mostly unique to each of the four human cancer cell lines HepG2, LNCaP, MCF7, and T47D.
Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS‐mutant relapsed or refractory myeloid malignancies
Popplewell, Leslie , Boyiadzis, Michael , Foran, James M. , Platzbecker, Uwe , Vey, Norbert , Walter, Roland B. , Olin, Rebecca L. , Raza, Azra , Giagounidis, Aristoteles , Al‐Kali, Aref , Kadia, Tapan M. , Garcia‐Manero, Guillermo , Bauman, John W., Wu, Yuehui , Liu, Yuan , Schramek, Dan, Cox, Donna S. , Wissel, Paul , Kantarjian, Hagop M. , Borthakur, Gautam , Jabbour, Elias , Platzbecker, Uwe , Walter, Roland B , Kantarjian, Hagop

Cancer | March 19, 2016 | Volume: 122 | Issue: 12 | Pages: 1871-1879

10.1002/cncr.29986 | PMID 26990290 Get It

BACKGROUNDRAS/RAF/mitogen‐activated protein kinase activation is common in myeloid malignancies. Trametinib, a mitogen‐activated protein kinase kinase 1 (MEK1)/MEK2 inhibitor with activity against multiple myeloid cell lines at low nanomolar concentrations, was evaluated for safety and clinical activity in patients with relapsed/refractory leukemias.METHODSThis phase 1/2 study accrued patients with any relapsed/refractory leukemia in phase 1. In phase 2, this study accrued patients with relapsed/refractory acute myeloid leukemia (AML) or high‐risk myelodysplastic syndromes (MDS) with NRAS or KRAS mutations (cohort 1); patients with AML, MDS, or chronic myelomonocytic leukemia (CMML) with a RAS wild‐type mutation or an unknown mutation status (cohort 2); and patients with CMML with an NRAS or KRAS mutation (cohorts 3).RESULTSThe most commonly reported treatment‐related adverse events were diarrhea, rash, nausea, and increased alanine aminotransferase levels. The phase 2 recommended dose for Trametinib was 2 mg orally daily. The overall response rates were 20%, 3%, and 27% for cohorts 1, 2, and 3, respectively, and this indicated preferential activity among RAS‐mutated myeloid malignancies. Repeated cycles of trametinib were well tolerated with manageable or reversible toxicities; these results were similar to those of other trametinib studies.CONCLUSIONSThe selective, single‐agent activity of trametinib against RAS‐mutated myeloid malignancies validates its therapeutic potential. Combination strategies based on a better understanding of the hierarchical role of mutations and signaling in myeloid malignancies are likely to improve the response rate and duration. Cancer 2016;122:1871–9. © 2016 American Cancer Society.